Results 161 to 170 of about 19,412 (203)

Case Report: Short-term disease control with subsequent icotinib therapy in EGFR L858R/C797S, T790M-negative lung adenocarcinoma after osimertinib resistance. [PDF]

Front Oncol
Song S, Yao D, Liu J, Nie W, He M, Zhang J, Zhao J.   +6 more
europepmc   +1 more source

Correction: Maione et al. Amivantamab Plus Lazertinib and Platin-Based Chemotherapy Plus Osimertinib in EGFR-Mutant NSCLC: How to Choose Among Them and When Is Monotherapy with Osimertinib Still the Best Option? <i>Curr. Oncol.</i> 2026, <i>33</i>, 54. [PDF]

Curr Oncol
Maione P, Romano FJ, Gridelli C.
europepmc   +1 more source

Rescue of Suprasellar Metastasis of <i>EGFR</i>-mutant NSCLC by Daily Osimertinib Re-escalation With Filgrastim Support. [PDF]

In Vivo
Saito S, Matsuda S, Nakamura M, Takahashi R, Yamamoto R, Ibe M, Takamori M, Kitazono M.   +7 more
europepmc   +1 more source

Pharmacoeconomic Analysis of Osimertinib Compared to Earlier-Generation EGFR Inhibitors in EGFR-Mutated NSCLC: A Systematic Review. [PDF]

Cancer Med
Perrotta N, Coluccia A, Rossi F, Amato G, Polito G.   +4 more
europepmc   +1 more source

Correction: Efficacy and safety of first-line osimertinib monotherapy versus osimertinib plus platinum-based chemotherapy or amivantamab plus lazertinib in metastatic EGFR-mutated NSCLC: an indirect comparison. [PDF]

Front Oncol
Del Bono L, Ossato A, Gasperoni L, Vecchia S, Cancanelli L, Damuzzo V, Gori S, Tessari R, Sava T, Inno A.   +9 more
europepmc   +1 more source

Case Report: squamous transformation after long-term osimertinib in EGFR-mutant lung adenocarcinoma with retained EGFR/TP53 alterations. [PDF]

Front Oncol
Xu L, Zhang D, Chen X, Wang L, Liu Q.
europepmc   +1 more source

TRMT1-mediated tRNA m²₂G modification drives Osimertinib resistance via the ATXN3/USP25 axis in lung adenocarcinoma. [PDF]

Cell Death Dis
Li J, Jing B, Wang Y, Bai W, Wei Q, Zhu C, Ling X, Liu M, Huang K, Pan S, Dong H, Lu H, Qian J, Ji Y, Liu W, Zhong H, Zhang Y, Wu W, Zhai Y, Luo H, Lei H, Xu H, Wu Y, Chu T.   +23 more
europepmc   +1 more source

Development of a structurally distinct TopBP1 inhibitor that enhances PARP blockade and reverses osimertinib resistance. [PDF]

Sci Adv
Lin FT, Lin SJ, Liu K, Xiao Y, Wilhelms Garan LA, Folly-Kossi H, Lin WC.   +6 more
europepmc   +1 more source

MET Dependence Oversteps EGFR Dependence via Balancing Dimerization of the Receptor Tyrosine Kinases in Osimertinib-Resistant MET-Amplified, EGFR-Mutated Non-Small Cell Lung Cancer. [PDF]

Thorac Cancer
Yagami Y, Sato T, Yamamoto H, Matsuo H, Inoue R, Tsutsumi R, Kakegawa M, Nakahara Y, Sasaki J, Naoki K.   +9 more
europepmc   +1 more source

A plain language summary of the SAVANNAH study: savolitinib plus osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer with MET overexpression and/or amplification whose cancer had grown or spread on osimertinib. [PDF]

Future Oncol
de Marinis F, Kim TM, Bonanno L, Cheng S, Kim SW, Tiseo M, Chu Q, Proto C, Sacher A, Luo YH, Novello S, Hao D, Baik C, Bazhenova L, Lee JS, Cho BC, Cadranel J, Diep TB, Metro G, Narayanan P, Yoneshima Y, de Castro Carpeño J, Baldotto C, Yang JC, Sequist LV, Levy B, Hartmaier R, Igwegbe I, Poole L, Xu W, Ahn MJ.   +30 more
europepmc   +1 more source